{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:55:39Z","timestamp":1793368539868,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.berh.2020.101515","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:17:20Z","timestamp":1588825040000},"page":"101515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":319,"title":["Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Georgia","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shenoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant C.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2020.101515_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.berh.2020.101515_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.berh.2020.101515_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from The North American Consortium for histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Canc"},{"issue":"35","key":"10.1016\/j.berh.2020.101515_bib5","doi-asserted-by":"crossref","first-page":"59977","DOI":"10.18632\/oncotarget.19230","article-title":"A\u00a0systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.berh.2020.101515_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)61951-7","article-title":"Histiocytic medullary reticulosis","volume":"ii","author":"Scott","year":"1939","journal-title":"Lancet"},{"issue":"136","key":"10.1016\/j.berh.2020.101515_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/adc.27.136.519","article-title":"Familial haemophagocytic reticulosis","volume":"27","author":"Farquhar","year":"1954","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5","article-title":"Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis","volume":"44","author":"Risdall","year":"1979","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(85)80072-X","article-title":"Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection","volume":"106","author":"Hadchouel","year":"1985","journal-title":"J\u00a0Pediatr"},{"issue":"22","key":"10.1016\/j.berh.2020.101515_bib10","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.berh.2020.101515_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fped.2016.00047","article-title":"Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment","volume":"4","author":"Ishii","year":"2016","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00018-011-0835-y","article-title":"Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity","volume":"69","author":"Sieni","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.hoc.2015.06.007","article-title":"Pathogenesis of hemophagocytic lymphohistiocytosis","volume":"29","author":"Filipovich","year":"2015","journal-title":"Hematol Oncol Clin N Am"},{"issue":"11","key":"10.1016\/j.berh.2020.101515_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27344","article-title":"Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal disease","volume":"65","author":"Heeg","year":"2018","journal-title":"Pediatr Blood Canc"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.20062447","article-title":"Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis","volume":"204","author":"Crozat","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"24","key":"10.1016\/j.berh.2020.101515_bib17","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1182\/blood-2011-01-329607","article-title":"Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice","volume":"117","author":"Krebs","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","article-title":"ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice","volume":"127","author":"Rood","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib20","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/iai.57.2.590-595.1989","article-title":"Endotoxin-induced serum factor that stimulates gamma interferon production","volume":"57","author":"Nakamura","year":"1989","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0609.2006.00730.x","article-title":"Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis","volume":"77","author":"Schaer","year":"2006","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jaci.2014.11.030","article-title":"Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-\u03b3 receptor deficiency","volume":"135","author":"Tesi","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.berh.2020.101515_bib26","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/art.37958","article-title":"Interferon-\u03b3 mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice","volume":"65","author":"Canna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101515_bib27","series-title":"Interferon gamma (IFNg) is the driving mediator of secondary hemophagocytic lymphohistiocytosis (sHLH) in TLR9-mediated pathogenesis in mice and is correlated to disease parameters in children","author":"De Min","year":"2015"},{"issue":"8","key":"10.1016\/j.berh.2020.101515_bib28","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.3928\/19382359-20170717-01","article-title":"An overview of hemophagocytic lymphohistiocytosis","volume":"46","author":"Esteban","year":"2017","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.berh.2020.101515_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.berh.2020.101515_bib30","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/art.23734","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms","volume":"58","author":"Zhang","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2020.101515_bib31","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","article-title":"Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis","volume":"66","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2020.101515_bib32","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib33","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.berh.2020.101515_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","article-title":"Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation","volume":"46","author":"Romberg","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2020.101515_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","article-title":"Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein","volume":"3","author":"Chiossone","year":"2012","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib36","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.berh.2020.101515_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/AHMT.S109495","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc Health Med Therapeut"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000338179","article-title":"Critical imbalance of TNF-\u03b1 and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment","volume":"128","author":"Flammiger","year":"2012","journal-title":"Acta Haematol"},{"issue":"25","key":"10.1016\/j.berh.2020.101515_bib39","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Gene Immun"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/art.39933","article-title":"Inflammatory gene expression profile and defective interferon-\u03b3 and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients","volume":"69","author":"Put","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2020.101515_bib45","doi-asserted-by":"crossref","first-page":"108252","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00205575","article-title":"A\u00a0phase I trial of recombinant gamma interferon in patients with cancer","volume":"20","author":"Foon","year":"1985","journal-title":"Cancer Immunol Immunother"},{"issue":"9927","key":"10.1016\/j.berh.2020.101515_bib47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pathol.2019.09.011","article-title":"Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach","volume":"52","author":"Hue","year":"2020","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/imr.12791","article-title":"Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases","volume":"291","author":"Latour","year":"2019","journal-title":"Immunol Rev"},{"issue":"17","key":"10.1016\/j.berh.2020.101515_bib50","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A\u00a0consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.berh.2020.101515_bib51","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.berh.2020.101515_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2431-14-38","article-title":"Pancytopenia as an early indicator for Stevens-Johnson syndrome complicated with hemophagocytic lymphohistiocytosis: a case report","volume":"14","author":"Fan","year":"2014","journal-title":"BMC Pediatr"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib55","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaip.2018.11.050","article-title":"Hemophagocytic lymphohistiocytosis: clinical presentations and diagnosis","volume":"7","author":"Risma","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"15","key":"10.1016\/j.berh.2020.101515_bib56","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"issue":"11","key":"10.1016\/j.berh.2020.101515_bib58","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pbc.22359","article-title":"Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race","volume":"54","author":"Niece","year":"2010","journal-title":"Pediatr Blood Canc"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib60","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","article-title":"Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis","volume":"139","author":"Rosado","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pbc.25308","article-title":"Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden","volume":"62","author":"Meeths","year":"2015","journal-title":"Pediatr Blood Canc"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib62","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1542\/neo.20-6-e316","article-title":"Neonatal hemophagocytic lymphohistiocytosis","volume":"20","author":"McLean","year":"2019","journal-title":"NeoReviews"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0889-8588(05)70521-9","article-title":"Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis","volume":"12","author":"Janka","year":"1998","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1532\/IJH97.07012","article-title":"Nationwide survey of hemophagocytic lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib65","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib66","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1097\/MD.0000000000000451","article-title":"Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients","volume":"94","author":"Bae","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.berh.2020.101515_bib67","doi-asserted-by":"crossref","first-page":"294041","DOI":"10.1155\/2015\/294041","article-title":"Macrophage activation syndrome as onset of systemic lupus erythematosus: a case report and a review of the literature","volume":"2015","author":"Granata","year":"2015","journal-title":"Case Rep Med"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MPH.0000000000000872","article-title":"Kawasaki disease complicated with macrophage activation syndrome: a systematic review","volume":"39","author":"Garc\u00eda-Pav\u00f3n","year":"2017","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","article-title":"Macrophage activation syndrome in Kawasaki disease: more common than we thought?","volume":"44","author":"Wang","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib70","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00296-019-04442-1","article-title":"Macrophage activation syndrome in juvenile dermatomyositis: a systematic review","volume":"40","author":"Poddighe","year":"2019","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib71","first-page":"459","article-title":"The incidence of macrophage activation syndrome in children with rheumatic disorders","volume":"63","author":"Moradinejad","year":"2011","journal-title":"Minerva Pediatr"},{"issue":"22","key":"10.1016\/j.berh.2020.101515_bib72","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4037\/aacnacc2019463","article-title":"Hemophagocytic lymphohistiocytosis","volume":"30","author":"Skinner","year":"2019","journal-title":"AACN Adv Crit Care"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5045\/br.2013.48.4.258","article-title":"Posterior reversible encephalopathy syndrome in pediatric patients undergoing treatment for hemophagocytic lymphohistiocytosis: clinical outcomes and putative risk factors","volume":"48","author":"Lee","year":"2013","journal-title":"Blood Res"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib75","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2559.1998.00377.x","article-title":"Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis","volume":"32","author":"Ost","year":"1998","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPMD5TJEFOOVBW","article-title":"Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability","volume":"141","author":"Ho","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.berh.2020.101515_bib77","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ijlh.13032","article-title":"Significance of serum ferritin level in hemophagocytic lymphohistiocytosis diagnosis","volume":"41","author":"Zhao","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"10.1016\/j.berh.2020.101515_bib79","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00277-017-3072-0","article-title":"Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis","volume":"96","author":"Otrock","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib80","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-009-0391-5","article-title":"Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis","volume":"90","author":"Wang","year":"2009","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-011-1239-7","article-title":"Possible prediction of underlying lymphoma by high sIL-2R\/ferritin ratio in hemophagocytic syndrome","volume":"91","author":"Tabata","year":"2012","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.berh.2020.101515_bib82","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1182\/blood-2011-12-398958","article-title":"Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)","volume":"119","author":"Pagel","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.berh.2020.101515_bib83","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2020.101515_bib84","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib85","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib86","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Canc"},{"issue":"9","key":"10.1016\/j.berh.2020.101515_bib87","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib88","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/ajcp\/aqw076","article-title":"Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients","volume":"145","author":"Debaugnies","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/03009742.2016.1167951","article-title":"Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases","volume":"46","author":"Batu","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib90","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000161","article-title":"Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"2","author":"Ravelli","year":"2016","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.berh.2020.101515_bib92","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","article-title":"Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"78","author":"Minoia","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib93","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.berh.2020.101515_bib94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpeds.2017.06.005","article-title":"Development and initial validation of the macrophage activation syndrome\/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome","volume":"189","author":"Minoia","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"26","key":"10.1016\/j.berh.2020.101515_bib95","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","article-title":"Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH","volume":"1","author":"Hayden","year":"2017","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.berh.2020.101515_bib96","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.berh.2020.101515_bib97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/bmt.2008.232","article-title":"Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step","volume":"42","author":"Jordan","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.berh.2020.101515_bib99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","article-title":"Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"13","author":"Boom","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.berh.2020.101515_bib100","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0022-3476(96)70160-9","article-title":"Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases","volume":"129","author":"Mouy","year":"1996","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3476(96)70408-0","article-title":"Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine","volume":"128","author":"Ravelli","year":"1996","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib102","first-page":"508","article-title":"Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF","volume":"97","author":"Quesnel","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5152\/TurkPediatriArs.2015.3299","article-title":"Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period","volume":"50","author":"Barut","year":"2015","journal-title":"Turk Pediatri Ars"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib104","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2020.101515_bib105","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3389\/fimmu.2018.02162","article-title":"Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome","volume":"9","author":"Barsalou","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/01.rhu.0000081259.61370.eb","article-title":"Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy","volume":"9","author":"Tristano","year":"2003","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib107","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-010-1711-z","article-title":"Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India","volume":"32","author":"Singh","year":"2012","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.berh.2020.101515_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229708","article-title":"High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant","volume":"12","author":"Lind-Holst","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib109","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3109\/14397595.2013.844403","article-title":"Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome - successful use of PET- CT and Anakinra in its diagnosis and treatment","volume":"25","author":"Tayer-Shifman","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"14","key":"10.1016\/j.berh.2020.101515_bib110","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1177\/0961203313504634","article-title":"Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus","volume":"22","author":"Bakshi","year":"2013","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/s10165-009-0231-8","article-title":"Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus","volume":"20","author":"Kamiya","year":"2010","journal-title":"Mod Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2020.101515_bib112","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/art.38672","article-title":"Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults","volume":"66","author":"Kumakura","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib113","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.semarthrit.2015.07.004","article-title":"Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies","volume":"45","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib114","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jbspin.2011.10.015","article-title":"Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment","volume":"79","author":"Larroche","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2020.101515_bib115","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","author":"Wang","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report","volume":"6","author":"Sadaat","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"21","key":"10.1016\/j.berh.2020.101515_bib117","doi-asserted-by":"crossref","first-page":"e2401","DOI":"10.1212\/WNL.0000000000007517","article-title":"Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine","volume":"92","author":"Kim","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.1995.tb03302.x","article-title":"Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis","volume":"89","author":"Chen","year":"1995","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.berh.2020.101515_bib119","first-page":"533","article-title":"[Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP]","volume":"151","author":"Larroche","year":"2000","journal-title":"Ann Med Interne"},{"issue":"7","key":"10.1016\/j.berh.2020.101515_bib120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1473-3099(06)70524-2","article-title":"Tuberculosis-associated haemophagocytic syndrome","volume":"6","author":"Brastianos","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.berh.2020.101515_bib121","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MPH.0b013e3180f61be3","article-title":"Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"29","author":"Balamuth","year":"2007","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.berh.2020.101515_bib122","first-page":"364","article-title":"The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis","volume":"67","author":"Bosman","year":"2009","journal-title":"Neth J Med"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib123","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3346\/jkms.2008.23.3.439","article-title":"Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis","volume":"23","author":"Shin","year":"2008","journal-title":"J\u00a0Kor Med Sci"},{"issue":"19","key":"10.1016\/j.berh.2020.101515_bib124","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","article-title":"Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib125","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report","volume":"12","author":"Sin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib126","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.crohns.2012.05.002","article-title":"A\u00a0case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's disease patient on azathioprine, successfully treated with rituximab","volume":"7","author":"Fitzgerald","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"issue":"6","key":"10.1016\/j.berh.2020.101515_bib127","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/08880018.2014.920942","article-title":"Wolman's disease with secondary hemophagocytic lymphohistiocytosis","volume":"31","author":"Rabah","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5152\/tjh.2010.54","article-title":"Niemann - pick disease associated with hemophagocytic syndrome","volume":"27","author":"Karaman","year":"2010","journal-title":"Turk J Haematol"},{"issue":"4","key":"10.1016\/j.berh.2020.101515_bib129","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1097\/MPH.0000000000001208","article-title":"Hemophagocytic lymphohystiocytosis associated with type Ia glycogen storage disease","volume":"41","author":"D\u00fczenli Kar","year":"2019","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib130","first-page":"307","article-title":"Hemophagocytic lymphohistiocytosis syndrome associated with Gaucher disease type 2","volume":"31","author":"Gholamreza","year":"2014","journal-title":"Turk J Haematol"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib131","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-3476(00)90072-6","article-title":"Treatment of hemophagocytic lymphohistiocytosis with cyclosporin A and steroids in a boy with lysinuric protein intolerance","volume":"136","author":"Bader-Meunier","year":"2000","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib132","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib133","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.13837","article-title":"Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years","volume":"172","author":"Schram","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.berh.2020.101515_bib134","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide","volume":"168","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2020.101515_bib136","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cyto.2018.05.017","article-title":"Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis","volume":"110","author":"Sakumura","year":"2018","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.berh.2020.101515_bib137","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.13026","article-title":"Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis","volume":"191","author":"Shimizu","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2020.101515_bib138","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.berh.2020.101515_bib139","doi-asserted-by":"crossref","first-page":"108255","DOI":"10.1016\/j.clim.2019.108255","article-title":"Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus","volume":"208","author":"Usami","year":"2019","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.berh.2020.101515_bib140","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2020.101515_bib141","doi-asserted-by":"crossref","first-page":"46652","DOI":"10.1038\/srep46652","article-title":"Elevated circulating levels of the interferon-\u03b3-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2020.101515_bib142","first-page":"keaa161","article-title":"An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus","author":"Thomason","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib143","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2019-216030","article-title":"Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib144","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.berh.2020.101515_bib145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2020.101515_bib146","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clim.2019.07.005","article-title":"Macrophage activation syndrome in neonates born to mothers with adult-onset Still's disease: perinatal effect of maternal IL-18","volume":"207","author":"Shimizu","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2020.101515_bib147","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2019.03.001","article-title":"Cytokine profile of macrophage activation syndrome associated with Kawasaki disease","volume":"119","author":"Jinkawa","year":"2019","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.berh.2020.101515_bib148","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clim.2012.11.004","article-title":"Distinct cytokine profile in juvenile systemic lupus erythematosus-associated macrophage activation syndrome","volume":"146","author":"Shimizu","year":"2013","journal-title":"Clin Immunol"},{"issue":"21","key":"10.1016\/j.berh.2020.101515_bib149","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694220300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:27Z","timestamp":1761499287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694220300322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1521694220300322"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2020.101515","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2020.101515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101515"}}